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Epigenetic plasticity underpins cell potency, but the extent to which active turnover of DNA 
methylation contributes to such plasticity is not known and the underlying pathways are poorly 
understood. Here we use metabolic labelling with stable isotopes and mass spectrometry to 
quantitatively address the global turnover of genomic methylcytidine (mdC), 
hydroxymethylcytidine (hmdC) and formylcytidine (fdC) across mouse pluripotent cell states. 
High rates of mdC/hmdC oxidation and fdC turnover characterize a formative-like pluripotent 
state. In primed pluripotent cells the global mdC turnover rate is about 3-6% faster than can 
be explained by passive dilution through DNA synthesis. While this active component is largely 
dependent on Tet-mediated mdC oxidation, we unveil additional oxidation-independent mdC 
turnover, possibly through DNA repair. This process accelerates upon acquisition of primed 
pluripotency and returns to low levels in lineage committed cells. Thus, in pluripotent cells 
active mdC turnover involves both mdC oxidation-dependent and -independent processes. 
  




Methylation at position 5 of deoxycytidine (dC) is the most prominent nucleobase modification 
in higher eukaryotic genomes1. In mammals, genomic dC is methylated to 5-methyl-2’-
deoxycytidine (mdC) by the DNA (cytosine-5)-methyltransferases DNMT1, DNMT3a and 
DNMT3b, mostly, but not exclusively in the context of CpG dinucleotides1,2. These enzymes 
differentially contribute to establishing and maintaining genomic mdC patterns across cellular 
and organismal generations. Genomic mdC is further modified by iterative oxidation to 5-
hydroxymethyl-, 5-formyl- and 5-carboxyl-dC (hmdC, fdC and cadC, respectively) through the 
action of Ten-Eleven Translocation (TET) di-oxygenases3–5. Several classes of DNA binding 
factors display differential affinity for their target sequences depending on the dC modification 
state1. This is why genomic patterns of dC modification contribute to consolidation and 
propagation of gene expression states and chromatin structure, thus affecting fundamental 
processes such as cell fate determination, imprinting, X chromosome inactivation and genome 
stability1. 
In the last two decades methylation of genomic dC was shown to be rapidly removed in various 
biological contexts6. Several erasure mechanisms were proposed, including prevention of 
methylation maintenance, which results in passive dilution of the modified base through DNA 
replication, and active demethylation by enzymatic processes6 (Fig. 1a). Among the latter, 
oxidation of mdC to fdC or cadC by TET enzymes, followed by base excision repair (BER), 
mediated by the DNA glycosylases TDG5,7 and Neil1/28,9, is best characterized. Additional 
proposals invoke the involvement of other DNA repair pathways6 or direct C-C bond 
cleavage10–14. A third line of proposal posits deamination of genomic mdC and hmdC to 
thymidine (dT) and 5-hydroxymethyl-2’-deoxyuridine (hmdU), respectively, either by a 
cytosine deaminase of the AID/APOBEC family15–17 or by de novo DNA methyltransferases 
DNMT3a/b18. The resulting T:G or hmU:G mismatches would be then resolved by BER or non-
canonical mismatch repair (ncMMR)15,16,19,20. Finally, it was suggested that unmodified dC 
could be deaminated by AID and that long patch BER or ncMMR could lead to indirect 
co-removal of adjacent mC residues17,19,20. Currently, all these pathways are highly 
controversial. Conclusive evidence for their functional relevance in vivo is lacking6. It is 
however conceivable that different pathways operate at different stages during development. 
During early embryonic development, the epiblast transits through a spectrum of pluripotent 
states21. This transition can be modelled by cultivating mouse pluripotent stem cells (mPSCs) 
under specific conditions, which recapitulates dynamic expression and epigenetic changes, 
including a major global gain of mdC21. Conversely, reversion from partially and 
heterogeneously primed mPSC cultures to the naïve state involves downregulation of de novo 
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methyltransferases and collapse of DNA methylation maintenance with consequent global and 
passive (Tet enzyme-independent) loss of genomic methylation22. In contrast, little is known 
about the extent and nature of the turnover of modified genomic cytosines during the forward, 
developmentally relevant transition from naïve to primed pluripotent states. Here, we used 
metabolic labelling with stable isotope standards for highly accurate mass spectrometry based 
quantification of the global genomic mdC, hmdC and fdC turnover through a progression of 
pluripotent states. We show that upon acquisition of primed pluripotency roughly 3-6% of the 
methylome is actively turned over. Most of this active turnover is due to Tet-mediated mdC 




Genomic mdC oxidation kinetics decrease in primed mPSCs 
We cultured mPSCs under specific conditions to model the progression of the embryonic 
epiblast from naïve to primed pluripotency and investigate the kinetics and turnover of dC 
modification during this transition. In order to monitor priming conditions, we first made use of 
a mPSC line expressing an Oct4-YFP reporter23. After adaptation to naïve conditions in the 
presence of Gsk3 inhibitor CHIR99021 (CHIR), Mek1/2 inhibitor PD0325901 (also known as 
2i) and LIF, the cells were plated at low density in serum-containing medium supplemented 
with CHIR and the Tankyrase inhibitor IWR1-endo (serum/CR) as previously described24. Live 
cell microscopy over the course of 6 days without passaging showed that these cells rapidly 
formed monolayer colonies, which retained a remarkably homogeneous nuclear YFP signal 
across the culture (Extended Data Fig. 1a), indicating that under these conditions mPSC 
cultures may not lose pluripotency. Similarly intense and homogeneous YFP signals were 
observed when the same reporter line was permanently primed to mouse Epiblast Stem Cells 
(mEpiSCs) in serum-free, chemically defined medium supplemented with CHIR, IWR1, FGF-
2 and Activin A (CDM/CRFA; Extended Data Fig. 1a). Expression analysis of pluripotency 
factors in serum/CR cultures and CDM/CRFA EpiSCs revealed similarly reduced and 
increased transcript levels of naïve and primed pluripotency factors, respectively (Extended 
Data Fig. 1b), showing that these conditions support similarly primed states. Thus, even 
without prolonged passaging or in chemically defined conditions, CHIR/IWR1 treatment 
supports primed pluripotency.  
We then used ultra-high pressure liquid chromatography coupled to triple quadrupole mass 
spectrometry (UHPLC-MS2)25 to analyse global levels of genomic mdC and hmdC upon 
priming of mPSCs under the same conditions over five days. As previously reported26, the 
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transition from the naïve (2i/LIF) to a homogeneously primed pluripotent state involved a large 
increase of the global mdC levels, while the hmdC abundance dropped sharply. Both 
modifications reaching plateau levels by day 4 (Extended Data Fig. 2a). Global levels of 
genomic mdC and hmdC, similar to those in serum/CR cultures, were detected in Oct4-YFP 
mEpiSCs under serum-free conditions, excluding potential confounding effects of undefined 
serum composition. Note that under both serum-containing and serum-free conditions, we 
avoided supplementation with ascorbic acid, which greatly increases the levels of oxidized 
mdC derivatives27. The decrease of hmdC upon priming is consistent with a recent proteomic 
analysis showing that the levels of chromatin bound Tet1 and 2 proteins are markedly reduced 
in mEpiSCs compared to naïve mPSCs, while Tet3 protein is undetectable in both states28. 
Notably, replacing the Mek inhibitor with the Src inhibitor CGP77675 (conditions referred to as 
alternative 2i or a2i) results in relatively high genomic mdC levels, while gene expression 
patterns remain similar to those of naïve mPSCs 29,30. Our analysis showed that the expression 
pattern of pluripotency and early lineage specification factors under a2i/LIF conditions is 
intermediate between that of naïve and primed states. We found high levels of Tfcp2l1 and 
Klf4 transcripts relative to 2i/LIF (naïve) conditions, intermediate expression of Rex1, Stella 
and Prdm14, and low levels of Fgf5, Oct6, Otx2 and Dnmt3b relative to primed conditions 
(Extended Data Fig. 1b). This pattern is similar to that present in formative pluripotency, an 
intermediate state along the trajectory from naïve to primed pluripotency, during which 
competence for multi-lineage commitment is acquired31. High depth bisulfite amplicon 
sequencing revealed a gradual increase of CpG methylation at secondary imprints during the 
transition from a2i/LIF to serum/CR conditions (Extended Data Fig. 2b), as observed in early 
embryos32. Altogether, these data support that cultures transferred from a2i/LIF to serum/CR 
conditions recapitulate fundamental molecular processes of the progression to a genuine 
primed pluripotent state. Importantly, a2i/LIF and serum/CR conditions allow comparison of 
genomic cytosine modification dynamics between functionally distinct pluripotent states with 
substantial and comparable steady state levels of genomic mdC. Thus, we adopted a2i/LIF 
conditions both for routine mPSC maintenance and as starting state for further time course 
analyses of mPSC priming. 
We then monitored global cytosine modification kinetics during acquisition of primed 
pluripotency by metabolic labelling of the C5 substituent. To this end, we supplemented 
L-Methionine (Met)-free medium with isotopically labelled Met (m+4Met), whereby the methyl 
group provides a m+4 mass shift [methyl-13C, d3]. As for naturally occurring Met, m+4Met is 
incorporated into S-adenosylmethionine (SAM) and the 13CD3 (m+4) is then transferred to 
genomic dC by Dnmts, generating m+4dC. The latter can be sequentially oxidised by Tet 
proteins to hm+3dC, f+2dC and ca+1dC (Fig. 1a)25. 
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For accurate quantification of natural mdC, hmdC, fdC and heavy m+4dC, hm+3dC, f+2dC, 
we synthesised a corresponding series of even heavier isotopologues (Fig. 1b-[1-3]) and used 
these as internal standards for quantification by UHPLC-MS2. In this work cadC and ca+1dC 
were not quantified because a difference of one mass unit cannot be discriminated. We first 
compared the modification kinetics in cultures maintained constantly under a2i/LIF conditions 
to cultures undergoing priming in CHIR/IWR1 medium. In both cases we performed time 
course analyses over 2 days of labelling in the presence of m+4Met, which in the case of 
priming cultures was from day 3 to 5 after transfer to serum/CR medium (Fig. 1c,d; Extended 
Data Fig. 3). In priming cultures the rate of m+4dC oxidation to hm+3dC was clearly slower 
than under a2i/LIF conditions and accumulation of the further oxidized state f+2dC became 
undetectable upon priming. Thus, the transition to primed pluripotency determines a major 
decrease in global oxidation of genomic mdC, which is consistent with the drastically reduced 
steady state levels of genomic hmdC (Extended Data Fig. 2a). 
 
Oxidative turnover of genomic mdC in mPSCs 
To monitor the turnover of modified genomic cytosines we reversed the labelling schema 
described above. We first labelled cultures with m+4Met for five days and, after transferring 
the cultures to medium with natural Met, we measured the disappearance of the label over 
two days (Fig. 2a). Again, we compared cultures maintained constantly under serum/a2i/LIF 
conditions to cultures undergoing priming in serum/CR medium. For primed cultures the first 
two pulse days were in a2i/LIF medium, while the last three were in serum/CR medium, thus 
corresponding to the first three days of priming. To generate a reference for passive dilution 
of a genomic nucleoside through DNA synthesis, we co-labelled with an isotopically labelled 
2’-deoxythymidine having a mass shift of 12 units ([15N2,13C10]-dT; hereafter referred to as 
dT+12). Due to its highly efficient incorporation, dT+12 was co-pulsed only during the last day 
of the m+4Met pulse (Fig. 2a). Thereafter, dT+12 was chased together with m+4Met. 
Remarkably, while in most cases the levels of modified cytosines readily declined with the 
onset of the chase, under a2i/LIF conditions hm+3dC and f+2dC accumulated for the first 12 
and 24 hours, respectively (Fig. 2b). This shows again that the rate of Tet-mediated oxidation 
is quite high in mPSCs under a2i/LIF conditions and declines sharply upon priming, as already 
seen with the time course analysis during m+4Met labelling (Fig. 1b,c). Notably, under a2i/LIF 
conditions the decline of f+2dC after 36 h is steep, pointing to high turnover of fdC. Although 
under priming conditions oxidation of mdC to hmdC and fdC was hardly detectable in labelling 
time course experiments (Fig. 1), in pulse chase experiments the decline of labelled hmdC 
and fdC was slower than that of dT+12, clearly showing that some mdC and hmdC oxidation 
still takes place (Fig 2b). Importantly, upon priming m+4dC turnover was faster than the dilution 
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rate of dT+12 (Fig. 2c; Extended Data Fig. 4a), revealing the presence a component that 
cannot be explained by passive dilution through DNA synthesis. 
To assess the contribution of Tet-dependent oxidation to this active component, we performed 
the same pulse/chase experiment under priming conditions (Fig. 2a, upper part) with E14tg2a 
mPSCs lacking all three Tet proteins (Tet triple knockout, alias Tet TKO)33 as well as parental, 
Tet 1-3 proficient E14tg2a cells (Fig. 3). In the parental cell line, turnover of genomic m+4dC 
was again clearly faster than passive dilution of dT+12. After averaging the data from three 
such pulse chase experiments with wt mPSC lines, a paired two-tailed T-test showed high 
significance (P = 0.0053) for the deviation between m+4dC and dT+12 decay rates. This 
accounts for an active component of global mdC turnover involving 3-6% of the methylome, 
depending on the time point (Fig. 2f). In contrast, in the genome of Tet TKO cells the decline 
rate of m+4dC was essentially indistinguishable from that of dT+12 (Fig. 3). This shows that 
the active component of the mdC turnover is indeed largely dependent on the presence of Tet 
enzymes, and thus mostly due to mdC oxidation. 
 
Additional non-oxidative mdC turnover in mPSCs 
Next to oxidative mdC turnover, we investigated potential deamination of mdC to dT (mdU)15. 
Upon metabolic labelling with m+4Met, deamination of m+4dC would generate m+4dU, that 
is dT bearing the m+4 methyl group (Fig. 1a). In order to investigate this process quantitatively 
we synthesised the isotopologue dT-[13C5,15N2] (Fig. 1b-[4]) and used it as a standard for 
UHPLC-MS2 analysis. As the source of methyl group for de novo dT biosynthesis is serine 
through 5,10-methylenetetrahydrofolate and not methionine through SAM, it is expected that, 
upon supplementation of the medium with m+4Met, m+4dC is the only source of m+4dU. To 
verify this expectation we made use of mPSCs lacking all catalytically active Dnmts (Dnmt 
TKO), and therefore devoid of genomic mdC34. After priming in the presence of m+4Met, 
m+4dU was clearly detected in the genome of wt mPSCs, but not in Dnmt TKO cultures 
(Extended Data Fig. 3). Thus, generation of m+4dU strictly requires the formation of genomic 
m+4dC, showing that m+4dU originates exclusively through deamination of m+4dC. 
Direct deamination of genomic mdC would generate T:G mismatches, which, if not efficiently 
repaired, would be highly mutagenic. Despite this, we detected substantial accumulation of 
m+4dU in genomic DNA (gDNA), whenever cultures were provided with m+4Met (Fig. 1-5, 
Extended Data Fig. 3-5,7). To explain this observation we considered an alternative scenario 
in which m+4dC is released from the genome as soluble m+4dC/m+4dCMP, possibly through 
a DNA repair process. Deamination of soluble m+4dC/m+4dCMP by Cytidine and 
Deoxycytidylate deaminases (Cda and Dctd)35, would generate soluble m+4dU/m+4dUMP, 
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which could be phosphorylated and re-incorporated into the genome through DNA synthesis 
(Fig. 4a). To test whether m+4dU is generated along this pathway, we supplemented the 
medium with m+4Met and increasing concentrations of unlabelled dT. The latter was added 
to outcompete the incorporation of soluble m+4dU/m+4dUMP into gDNA and to allosterically 
inhibit Dctd36. Indeed, we detected a dT dose-dependent reduction of genomic m+4dU in 
priming mPSC cultures (Fig. 4b). This result supports the idea that genomic m+4dU originates 
in large part from a pool of soluble precursor. 
To probe whether deamination of m+4dC takes place within gDNA or at the level of soluble 
nucleoside/nucleotide pools, we generated mPSC with double deficiency for Cytidine 
deaminase (Cda) and Deoxycytidylate deaminase (Dctd) through CRISPR/Cas9-mediated 
gene editing (hereafter referred to as CD-DKO; Supplementary Fig. 1a,b). Genomic 
sequencing showed that three of the isolated clonal lines bear compound biallelic Cda and 
Dctd mutations incompatible with the expression of functional enzymes (Supplementary 
Figures 1c-e and 2a,b). All three CD-DKO clones grew at slower rates than parental wt cells, 
a phenotype which was at least partially relieved by supplementation of dT (Supplementary 
Fig. 1f). This indicates that deamination of (d)C/dCMP by Cda and/or Dctd provides substantial 
amounts of (d)U/dUMP for biosynthesis of (d)T/dTMP by Thymidine synthase to support DNA 
replication. This observation is fully consistent with previously reported dT auxotrophy of Dctd 
deficient somatic cell lines37. As two of the CD-DKO clones grew particularly poorly under 
serum/CR priming conditions, we first used serum/LIF medium for metabolic labelling with 
m+4Met under priming conditions. Importantly, while the genomic content of mdC/m+4dC was 
the same as in parental wt cells, only background levels of m+4dU could be measured in all 
three CD-DKO clones (Fig 4c). The same result was obtained with CD-DKO clone 40 upon 
priming in serum/CHIR/IWR1 medium (Fig. 4d). These results clearly show that all measurable 
genomic m+4dU originates from a process involving direct release of m+4dC/m+4dCMP from 
the genome, its deamination to m+4dU/m+4dUMP in the soluble pool and (re)-incorporation 
into the genome through phosphorylation and DNA synthesis.  
Although our data do not support deamination of mdC directly within the genome, it is 
important to consider the limitations of our UHPLC-MS2 method. In UHPLC the overwhelming 
amount of natural dT present in the genome co-elutes with m+4dU and outcompetes it during 
ionization for the capture of charge. This strong ion suppression effect reduces the m+4dU 
signal and results in a high limit of detection (LOD). To put this into perspective, our LOD for 
m+4dU (1x10-5 per nucleotide) is about 10-100 times higher than typical global levels of fdC, 
which is a relatively stable dC modification with an epigenetically relevant role38,39. In regard 
to this and previous reports of direct mdC deamination within gDNA15,18, we cannot fully 
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exclude that deamination of a few m+4dC residues within the genome trigger long patch BER 
and/or ncMMR19,20, leading to the release of larger amounts of m+4dC.  
In order to minimize ion suppression and gain sensitivity, we double labelled wt and CD-DKO 
mPSCs with m+4Met and a dC nucleoside where 9 hydrogen atoms are replaced with 
deuterium. After incorporation into the genome, dC[D9] is methylated to m+4dC[D8], which 
deaminates to m+4dU[D8] (a dT with eleven D atoms and a +12 mass shift; Extended Data 
Fig. 6a). This massive H-to-D exchange was expected to the shift UHPLC retention time 
slightly, allowing m+4dU[D8] to escape co-elution with dT. Indeed, co-injection tests showed a 
slightly shorter retention time for dT[D8] relative to dT (Extended Data Fig. 6b). For m+4dU[D8] 
we saw an even shorter retention time. After double labelling with m+4Met and dC[D9] we 
detected m+4dU[D8] confidently in wt mPSCs (Extended Data Fig. 6c). In addition, we 
sporadically detected small m+4dU[D8] peaks in technical replicates of CD-DKO samples. 
After integration of these sporadic signals, the corresponding values were invariably below 
LOD. Although we cannot exclude that these signals are caused by background processes, 
taking them into consideration allows us to estimate between 500 and 5000 genomic 
deamination events per cell in the course of our labelling experiment. According to an empirical 
rate constant for spontaneous hydrolytic deamination of mdC in solution40, only around 20 
such events would be expected to take place. Therefore, we cannot exclude the occurrence 
of a small amount of genomic deamination above the rate of spontaneous hydrolysis at levels 
of 1x10-6-1x10-7 per nucleotide. 
 
Tet enzymes do not trigger mdC-to-dT turnover 
Conversion of m+4dC into m+4dU does not require oxidized intermediates. However, it was 
recently suggested that in the zygote Tet3 generates undefined DNA lesions, triggering repair-
mediated erasure of genomic methylation from the paternal genome41. Also, hmdC may mark 
DNA damage sites and promote their repair4242 or even elicit DNA repair by selectively 
recruiting endonucleases like Srap143 and Endonuclease G44. We therefore considered 
whether Tet proteins contribute to the turnover of genomic mdC into dT by generating hmdC 
or low levels of DNA lesions such as hmdU25, which triggers BER initiated by the DNA 
glycosylase Smug1. To this aim we primed Tet TKO and parental E14tg2a mESCs in the 
presence of m+4Met. Surprisingly, higher levels of genomic m+4dU were detected in the 
absence of Tet enzymes (Extended Data Fig. 7). Similarly, analysis of the pulse chase 
experiment also revealed a tendency to higher accumulation of m+4dU in Tet TKO mPSCs at 
later chase time points (Fig. 3b). Therefore, in pluripotent cells Tet proteins do not seem to 
trigger DNA repair events that may contribute to turnover of mdC into dT.  




mdC-to-dT turnover is developmentally regulated 
To investigate whether oxidation-independent mdC turnover is regulated during the transition 
to primed pluripotency, we first compared the genomic abundance of m+4dU in the time 
course and pulse-chase experiments under a2i/LIF and priming conditions described above 
(Fig. 1-3, Extended Data Fig. 3). In time course experiments, progressive accumulation 
m+4dU was much faster and about five times higher under priming conditions (Fig. 1, 
Extended Data Fig. 3). Also, m+4dU was the only m+4dC derivative that accumulated during 
label chase under priming conditions, though to different extents in the two cell lines tested 
(Fig. 2e,3b and Extended Data Fig. 4b). Thus, in contrast to the observed decline of mdC 
oxidation (Fig. 1,2, Extended Data Fig. S3), these results reveal increased rates of mdC-to-dT 
turnover upon acquisition of primed pluripotency. This anti-correlation suggests that oxidation-
independent mdC turnover may serve at least in part as a supplementary pathway for the 
erasure of dC methylation. However, this process cannot involve more than 1% of the 
methylome, as in primed Tet TKO mPSCs there was no apparent difference between global 
mdC turnover and DNA replication-dependent passive dilution (Fig. 3a: decay of m+4dC and 
dT+12, respectively). 
At last, we compared oxidation-independent mdC-to-dT turnover in pluripotent states with 
various lineage committed cell types, including primary and immortalized embryonic 
fibroblasts, neural stem cells (NSCs)45 and HeLa cells. Although primed pluripotent cells were 
labelled with m+4Met for only two to three days, m+4dU reached higher levels in their genome 
than in those of any of the somatic cell types labelled for substantially longer periods, ranging 
from 6 to 12 days (Fig. 5a). This clearly shows that in lineage committed cells oxidation-
independent mdC turnover is substantially lower than in primed pluripotent cells. In addition, 
the rate of mdC-to-dT turnover is clearly not proportional to the global genomic abundance of 
mdC either between pluripotent states or among pluripotent and lineage committed cells. In 
particular, among the latter, mdC-to-dT turnover is clearly more active in NSCs than in 
fibroblasts, despite the mdC genomic content being at least 20% lower in NSCs. These 




Recent methylome analysis of matched clonal and polyclonal cell populations46 and studies 
on the contribution of Dnmt3 proteins to DNA methylation maintenance47,48 suggested that in 
heterogeneously primed mPSCs cultures (serum/LIF) genomic mdC undergoes higher 
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dynamic turnover as compared to differentiated somatic cells. However, the extent and 
especially the nature of this turnover have not been addressed. Previously, Bachmann et al. 
reported a pulse-chase experiment with m+4Met and a short pulse time to estimate the global 
turnover of genomic mdC and hmdC in mPSCs under naïve conditions (2i/LIF)49, where the 
levels of dC modifications are far lower. 
Here, we report the analysis of on- and off-rate kinetics for genomic dC modifications upon 
transition to primed pluripotency. We show that in mPSCs under a2i/LIF conditions, which 
display expression and genomic methylation patterns that are intermediate between naïve and 
primed pluripotent states (formative state)31, the rates of mdC oxidation to hmdC and further 
to fdC are quite sustained. The removal/conversion of fdC is very rapid. This points to a very 
dynamic equilibrium for fdC under these conditions. It is tempting to speculate that these high 
levels of oxidative turnover may underlie the frequent periodical oscillations in global mdC 
levels recently identified through single cell analysis in partially (and heterogeneously) primed 
serum/LIF cultures50. In contrast to the high levels of mdC oxidation in a2i/LIF conditions, upon 
transition to primed pluripotency, the global oxidation rates of mdC and hmdC as well as the 
removal of hmdC and fdC decline drastically. Despite this, the global turnover rate of genomic 
mdC is 3-6% faster than can be accounted for by passive dilution through DNA synthesis 
(DNA replication and repair; Fig. 5b). This difference is largely due to Tet-mediated mC 
oxidation. Evidence for passive erasure of dC methylation based on impairment of its 
maintenance has been provided for primordial germ cells, preimplantation embryonic 
development and the reversion from heterogeneous partially primed/formative states present 
in serum/LIF cultures to the naïve pluripotent state1,22. We suggest that against the backdrop 
of global gain and maintenance of dC methylation in the forward developmental transition from 
naïve to primed pluripotency an active demethylation mechanism may be more attainable than 
preventing maintenance of dC methylation at selected sites. This could be especially the case 
at loci with a highly accessible chromatin conformation like actively transcribed genes. 
By tracing the origin of genomic m+4dU to the deamination of soluble m+4dC, we show that 
a small part of genomic mdC is turned over by a process that involves the direct excision of 
mdC from the genome (Fig. 5b). Although the nature of this process and the events triggering 
it remain to be determined, we speculate that DNA repair is responsible for the release mdC. 
While we show that TET proteins are clearly not involved in triggering or targeting this non-
oxidative mdC turnover, our data neither support nor rule out that low levels of direct enzymatic 
deamination of genomic mdC may trigger a DNA repair process underpinning the turnover 
pathway. Importantly, this process is not proportional to global genomic mdC levels, either 
between pluripotent states, among lineage committed cell types or between pluripotent and 
committed cells, indicating that it could be developmentally regulated. Interestingly, the levels 
of oxidation-independent mdC turnover show an inverse correlation with mdC oxidation rates 
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across pluripotent states and seem to be slightly more sustained in Tet deficient cells, pointing 
to a possible function as alternative or supplementary mechanism dedicated to active erasure 
of cytosine methylation. 
In summary, we show that upon priming of pluripotent cells a significant fraction of mdC (3-
6%) vanishes after oxidation to hmdC, fdC and cadC. A smaller fraction of mdC is removed 
from the genome by cleavage of phosphodiester bonds, likely as part of an unknown DNA 
repair process. Once released in the soluble pool, mdC is deaminated to dT, which is 
reintegrated into the genome. Finally our data are inconclusive regarding a very low level of 
genomic mdC deamination, which would generate dT:dG mismatches and trigger DNA repair. 
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Figure 1. Drastic reduction of 
global genomic mdC oxidation 
and increase of mdC to mdU 
conversion upon transition to 
primed pluripotency. 
a) Proposed de-modification 
pathways for genomic 
C5-cytosine modifications and 
expected labelled mdC 
derivatives upon metabolic 
labelling with m+4Met. b) 
Nucleoside isotopologues used as 
internal standards for UHPLC-
MS2 analysis. Black dots in the 
ribose represent 13C atoms. c and 
d) Time course analysis of 
genomic dC derivatives upon 
metabolic labelling with m+4Met 
under a2i/LIF (c) and priming 
conditions (serum/CR; d). The 
labelling/time course schedules 
are shown at the top. Global levels 
of unlabelled mdC (pale yellow) 
and m+4dC (dark yellow), hm+3C 
(blue) and f+2C (green) are shown 
as individual values of replicate 
measurements (n=3: black 
squares) and their means (bars) 
from single samples. An 
independent biological replicate 
for both c and d is shown in 
Extended Data Fig. 3. LOD = limit 
of detection. 
 




Figure 2. Turnover of genomic mdC and its derivatives under a2i/LIF and priming conditions. 
a) Workflow of m+4Met and dT+12 pulse-chase experiments with wild type mPSCs under a2i/LIF and 
priming (serum/CR) conditions. b and c) Global profiles of the indicated labelled cytosine derivatives 
and dT+12 in the genome of mPSCs under a2i/LIF (b) and priming conditions (serum/CR; c) upon 
chasing of m+4Met. Each panel shows fold change values relative to the highest level for each 
modification from an individual experiment. Dashes represent single technical replicate measurements 
(n=3) from single samples. Full lines in b join mean values, while in c dashed lines represent first order 
decay curves fitted to mean values. In b and c the area between the m+4dC and dT+12 lines is 
shadowed in yellow and purple, respectively. d and e) Absolute levels of genomic m+4Met from the 
same samples as in b and c, respectively. Black squares represent single technical replicate 
measurements (n=3) from single samples and bars show their mean values. The experiment under 
priming conditions (c,e) was independently repeated once in the same mPSC line (Extended Data 
Figure 4) and once in E14tg2a (Fig. 3). f) Percent of difference between fold changes of dT+12 and 
m+4dC in wt mPSCs under serum/CR conditions from independent biological experiments (n=3; Fig. 
2c,3a and Extended Data Fig. 4a). Large blue dots and error bars represent mean values and SD, 
respectively. 




Figure 3. The active component of mdC turnover in primed pluripotent cells largely depends on 
Tet proteins. 
m+4Met and dT+12 pulse-chase experiment with parental and Tet TKO E14tg2a mPSCs under priming 
conditions (serum/CR; equivalent to Fig. 2c,e). Profiles of global genomic levels of the indicated labelled 
cytosine derivatives and dT+12 are shown. a) m+4dC and dT+12 fold change values relative to the 
highest data point for each modification. Upper panels display magnifications of dashed frames in lower 
panels. Dashes represent single technical replicate measurements (n=3) from single samples and 
dashed lines are first order decay curves fitted to their means. In middle panels the area between the 
m+4dC and dT+12 lines is shadowed in purple. b) Absolute levels of genomic m+4Met from the same 
samples as in a. Black squares represent individual technical replicate measurements (n=3) from single 
samples and bars show their mean values. This experiment was not independently replicated. 




Figure 4. All detectable mdC deamination takes place in the soluble pool. 
a) Potential pathways for the conversion of genomic m+4dC into genomic m+4dU. b) wt mPSCs were 
primed under CHIR/IWR1 (serum/CR) conditions in the presence of m+4Met and growing 
concentrations of unlabelled dT in the culture medium as indicated. c) wt and CD-DKO clones mPSCs 
were grown under serum/LIF conditions in the presence of m+4Met. d) wt and CD-DKO clone #40 
mPSCs were metabolically labelled with m+4Met under serum/CR priming conditions. In b-d priming 
and labelling was for five days. Global genomic contents of mdC, m+4dC (upper panels) and m+4dU 
(lower panels) are shown as individual values of replicate measurements (n=3: black squares) from 
single samples and their means (bars). LOD = limit of detection. Experiments in b and c were repeated 
three times with very similar results. 
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Figure 5. Oxidation-independent 
mdC-to-dT turnover is 
developmentally regulated. 
a) Cultures of mPSCs in a2i/LIF 
and primed states, primary 
(pmEFs) and immortalized mouse 
embryonic fibroblasts (imEFs and 
NIH3T3), HeLa and mPSC-derived 
neural stem cells (mNSCs) were 
labelled for the indicated number of 
days (d) with m+4Met. Asterisks 
indicate cases where distinct 
parallel cultures in the absence and 
presence of m+4Met were used to 
measure global levels of genomic 
mdC and m+4dU, respectively. In 
all other cases mdC, m+4dC and 
m+4dU were measured from the 
same culture labelled with m+4Met. 
Individual values of replicate 
measurements (n=3: black 
squares) from single samples and 
their means (bars) are shown. Only 
the first two samples were 
independently replicated a second 
time. a2iL = a2i/LIF; CR = 
CHIR/IWR1; FA = FGF-2/Activin A; 
CDM = Chemically Defined 
Medium. b) Schematic summary of 
the dC modification turnover 
pathways identified in primed 
pluripotent cells. Deamination of 
genomic mdC could not be 
detected and may occur only at 
levels below the sensitivity of our 
assay. 
  





Medium components were from Sigma unless specified otherwise. Basal medium for mPSC 
culture was DMEM high glucose containing 10% FBS (Pan-ES, Pan-Biotech), 2 mM L-Alanyl-
L-Glutamine, 1x MEM Non-essential Amino Acid Solution and 0.1 mM β-mercaptoethanol. 
mPSC lines were routinely maintained in basal medium supplemented with 1000 U/mL LIF 
(ORF Genetics), 3 µM CHIR99021 and 7.5 µM CGP77675 (a2i). For adaptation to 2i/LIF 
conditions CGP was replaced with 1 µM PD0325901. For priming, mPSC basal medium was 
supplemented with 1.5 µM CHIR99021 and IWR1-endo at 2.5 µM as previously reported24,51. 
For experiments under serum/LIF conditions basal medium was supplemented exclusively 
with 1000 U/ml LIF. Small molecule inhibitors were purchased from Selleckchem (CHIR, PD, 
IWR1), Axon Medchem (CHIR, CGP, PD, IWR1) or MedChemExpress (CHIR). Gelatin coating 
was used for all mPSCs cultures in serum containing medum. Wherever not otherwise stated 
experiments with wild type mPSCs were performed with an embryonic stem cell line derived 
from F1 129/C57Bl6 hybrid embryos52. For metabolic labelling experiments with m+4Met 
under all conditions mPSC basal medium was generated with L-Methionine- and L-Cysteine-
free DMEM (Sigma or Life Technologies) supplemented with  0.2 mM m+4Met ([methyl-
13C,d3]) and L-Cysteine (both from Sigma). In pulse-chase experiments, dT+12 
([15N2,13C10]-dT; BACH UG, Hamburg) was supplemented at 5 µM. dC[D9] (Silantes GmbH, 
Munich) was supplemented to culture medium at 100 µM. EpiSCs in chemically defined 
serum-free medium (CDM) were derived from the Oct4-YFP reporter mPSC line OLY2-123. 
These were first adapted to CDM supplemented with CHIR, PD and LIF as reported above, 
then transferred to CDM supplemented with CHIR, CGP, 12 ng/ml FGF-2 (Miltenyi Biotec) and 
20 ng/ml Activin A (PeproTec) and maintained in the latter medium by passaging as small cell 
clusters using 5 mM EDTA in Hank’s balanced salt solution without Mg2+, Ca2+ and sodium 
carbonate supplemented with 10 mM HEPES buffer. CDM was DMEM high glucose 
supplemented with 1x NEAA, 2 mM L-Alanyl-L-Glutamine, 15 µg/ml human recombinant 
Insulin, 10 µg/ml human holo-Transferrin (Merck), 12.5 mg/ml AlbuMAX I (Life Technologies) 
0.7 µg/ml vitamin B12, 1.8 ng/ml biotin, 0.75 µM ZnSO4 and 2.6 nM CuSO4. Laminin 521 
coating was used for all mPSC cultures in CDM. The neural stem cell line ENC1 was 
generated and cultured as previously described45. ENC1 cells were labelled with m+4Met 
([methyl-13C,d3])  in DMEM/F-12 generated with L-Methionine-free DMEM supplemented with 
N253 and 20 ng/ml each of FGF-2 and EGF (PerpoTech). Primary mEFs (CF-1, Applied 
StemCell) were cultured in mPSC basal medium. Fibroblast cell lines and HeLa cells were 
cultured in DMEM containing 10% FBS (Life Technologies), 2 mM L-glutamine and 0.1 mM β-
mercaptoethanol. 
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Generation of CD-DKO mPSCs by CRISPR/Cas9 editing  
Single guide RNAs were designed over exon1 and 4 of Cda and Dctd, respectively 
(Supplementary Fig. 1), using CRISPR Design Tool (http://crispr.mit.edu/). Oligonucleotides 
used for construction of Cas9/gRNA expression vectors are listed in Supplementary Table 1. 
The oligonucleotides were annealed and cloned in the BbsI site of pSpCas9-2A-Puro (PX 459; 
Addgene Plasmid 48139)54. Cas9/gRNA expression vectors targeting both Cda and Dctd were 
co-transfected in wt J1 mPSCs using Lipofectamine 2000 (Life Technology) according to the 
manufacturer’s instructions. Two days after transfection cultures were selected with 1 µg/ml 
puromycin for two days and subcloned by limiting dilution. Clones were screened using the 
Surveyor Mutation Detection Kit (Transgenomics) and potential compound biallelically 
targeted clones were subject to sequencing. For reverse transcription-PCR, RNA was isolated 
with the ZR-Duet DNA/RNA MiniPrep Kit (Zymo Research) and first strand cDNA synthesis 
was as previously described55. Primers were used to amplify the Cda cDNA are reported in 
Supplementary Table 1. For western blot analysis of Dctd whole cell extracts and purified 
human recombinant DCTD protein56 were probed with a rabbit anti-DCTD antibody36. 
 
Isolation of genomic DNA and UHPLC-MS2 analysis 
Isolation, digestion and UHPLC-MS2 analysis of gDNA samples were performed as described 
previously described25,57 with the following modifications: for every technical replicate 4 µg of 
gDNA were digested and analysed; the enzyme mixture including S1 Nuclease, Antarctic 
Phosphatase and snake venom Phosphodiesterase was used for digestion; the digestion 
mixture was supplemented with 0.8 µM Tetrahydrouridine (Abcam) to inhibit potential cytidine 
deaminase activity in enzyme preparations. 
 
Reverse transcription (RT)-qPCR analysis 
Total RNA was isolated from the lysate flow-throughs obtained upon genomic DNA isolation 
with silica spin columns. RNA isolation from the flow-throughs was performed as described in 
the Quick-DNA/RNA Miniprep kit (Zymo Research, D7001). In-column DNase I digestion was 
performed to minimize carryover of residual genomic DNA. One microgram of total RNA was 
reverse transcribed with the iScript cDNA Synthesis Kit and the cDNA product equivalent to 
50 ng of total RNA were amplified using iTaq Univesal SYBR Green Supermix (both from 
BioRad) on a qTOWER³/G cycler (Jena Biosciences). qPCR primers are reported in  
Supplementary Table 1. Each primer pair spanned across one intron except fom Oct6 cDNA 
amplifications as Pou3f1 (the gene coding Oct6) is intronless. qPCR reactions were also 
performed in parallel for every target/sample by omitting the reverse transcriptase to control 
for signals generated from residual genomic DNA (intronless Oct6 transcript, relatively short 
introns and spliced pseudogenes). An RT-qPCR assay for Gapdh transcripts was used as 
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housekeeping transcript reference to calculate ΔCt values. Fold change values were 
calculated with the ΔΔCt method. 
 
High depth targeted bisulfite amplicon sequencing and analysis 
Genomic DNA (1-2 µg) was bisulfite treated using the EpiTect Bisulfite Kit (Qiagen 59104). 5’ 
overhangs compatible with Illumina TruSeq and Nextera adapters were appended to the locus 
specific primers (Supplementary Table 1). Approximately 10 ng of bisulfite converted DNA 
were amplified with HotStar-Taq plus DNA polymerase (Qiagen). PCR products were 
analyzed by agarose gel electrophoresis and quantified by densitometry using ImageJ 
(version 1,52d). Similar amounts of these primary amplicons were used as templates for a 
second round of amplification with i5 and i7 Indexing Primers (Supplementary Table 1). PCR 
products were again analyzed by agarose gel electrophoresis and, after purification with 
CleanNGS magnetic beads (CleanNA), they were quantified by fluorometry with Quant-iT 
PicoGreen Reagent (Thermo Fisher). Equimolar amounts of amplicons were then pooled and 
the size distribution of the final library was assessed on a Bioanalyzer (Agilent). The 2x300 
output mode for dual indexed sequencing was used on a MiSeq instrument (Illumina). Size, 
numbers of CpG sites and genomic coordinates of targeted regions are reported in 
Supplementary Table 2. Sequenced reads were trimmed for adaptor sequences and masked 
for low-quality sequence using TrimGalore version 0.5.0, Cutadapt version 1.17. Trimmed 
reads were mapped to imprint-containing, bisulfite converted chromosomes 2, 7, 11,12 and 
17 from mm10 using bsmap v2.90. Methylation ratios were extracted from bam files using a 
custom Python script and tabulated as a matrix table from which the box plot in Extended Data 
Fig. 2b was generated by means of an R script. Raw sequencing data and matrix table are 
available at GEO with accession number GSE152174. 
 
Synthetic Procedures 
The synthesis of labelled nucleosides standards is reported in the Supplementary Information 
file as Supplementary Note. 
 
Data availability statement 
The targeted bisulfite amplicon sequencing data on which Extended Data Fig. 2b is based are 
available at GEO with accession code GSE152174. The authors declare that all other data 
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Supplementary Figure 1. Generation and characterization of CD-DKO mPSCs (related to 
Fig. 4). 
a and b) Schematic representations of gene body (top), transcript (middle, A only) and protein 
(bottom) for mouse Cda (a) and Dctd (b). Exons are represented by blue boxes, with UTR 
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regions in lighter colour. The positions of gRNAs are indicated by green rectangles over the 
gene, while green triangles indicate the approximate positions of the expected truncation of 
the protein. The catalytic domains are shown along with the two Zn2+ co-ordinating motifs, 
which are conserved across kingdoms of life among all cytosine nucleoside and 
monophosphate nucleotide deaminases, including the vertebrate-specific Aid/Apobec family. 
c) Genomic sequences of Cda and Dctd alleles as well as respective protein sequences for 
Cda and Dctd in CD-DKO clones. Antisense strands are shown so as to highlight the PAM 
sequences (bold type in wt sequence). The expected Cas9 cut sites are indicated by green 
triangles. The three clones are homozygous and heterozygous with respect to Cda and Dctd 
mutations, respectively. Mutations in Dctd were targeted to exon 4 and lead to termination of 
the frame before the second conserved catalytic motif. Note that, though exons 3 and 5 are in 
frame, alternative splicing events skipping the frameshifts in exon 4 would generate a protein 
lacking both conserved motifs involved in Zn2+ co-ordination, which would therefore lack 
catalytic activity.  d) Reverse transcription-PCR products from CDA transcripts in wt cells and 
CD-DKO clones resolved on a 10% non-denaturing polyacrylamide gel. The experiment was 
repeated twice with the same result. e) Western blot with an anti-Dctd antibody on whole cell 
extracts from wt and CD-DKO cells and purified recombinant Dctd protein. Cross-reactive 
bands are shown in the upper panel as loading control. As all the alleles detected in CD-DKO 
clones are expected to result in substantial protein truncations, the week signals visible in CD-
DKO lanes at approximately the same position as in wt and recombinant Dctd lanes are likely 
due to unspecific cross-reaction. f) Growth delay of CD-DKO mPSCs and partial rescue with 
dT. The same number of cells was plated for two days under a2i/LIF conditions with or without 
addition of 50 µM dT to the medium (only CD-DKO clones). Cell counts after two days of culture 
are shown. 
  





Supplementary Figure 2. Source data for Supplementary Fig. 1d and e 
a and b) Uncropped and unprocessed source images for Supplementary Fig. 1d and 
e, respectively. Unlabelled lanes on the left show molecular weight standards. 
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Supplementary Table 1 
Oligonucleotide/primer sequences used in this study. RT = Reverse Transcription. 
Name Sequence Application Reference 
    
mCda gRNA F CACCGAGCAGCCGCTGGACGTGCTC gRNA construct this work 
mCda gRNA R AAACGAGCACGTCCAGCGGCTGCTC gRNA construct this work 
mDctd gRNA F CACCGACATTCGTTACACGGGAACA gRNA construct this work 
mDctd gRNA R AAACTGTTCCCGTGTAACGAATGTC gRNA construct this work 
mCda F AAGGCCATCTCCGAAGGGTA RT-PCR this work 
mCda R TCTTCAGGTCCAAACGAGGC RT-PCR this work 
Dnmt3b Fw CTGGCACCCTCTTCTTCATT RT-qPCR 1 
Dnmt3b Rv ATCCATAGTGCCTTGGGACC RT-qPCR 1 
Fgf5 Fw AGGGGATTGTAGGAATACGAG RT-qPCR 3 
Fgf5 Rv TCTTGGAATCTCTCCCTGAAC RT-qPCR 3 
Klf4 Fw CGGGAAGGGAGAAGACACT RT-qPCR 3 
Klf4 Rv GAGTTCCTCACGCCAACG RT-qPCR 3 
Nanog Fw AAGTACCTCAGCCTCCAGCA RT-qPCR 4 
Nanog Rv GCTTGCACTTCATCCTTTGG RT-qPCR 4 
Otx2 Fw CATGATGTCTTATCTAAAGCAACCG RT-qPCR 5 
Otx2 Rv GTCGAGCTGTGCCCTAGTA RT-qPCR 5 
Oct6 Fw TTTCTCAAGTGTCCCAAGCC RT-qPCR 3 
Oct6 Rv ACCACCTCCTTCTCCAGTTG RT-qPCR 3 
Oct4 Fw AGGAAGCCGACAACAATGAG RT-qPCR 4 
Oct4 Rv ACTCCACCTCACACGGTTCT RT-qPCR 4 
Prdm14 Fw CTCTGGAGACAGGCCATACC RT-qPCR 3 
Prdm14 Rv GTCTGATGTGTGTTCGGAGTATGC RT-qPCR 3 
Tfcp2l1 Fw GGGGACTACTCGGAGCATCT RT-qPCR 3 
Tfcp2l1 Rv TTCCGATCAGCTCCCTTG RT-qPCR 3 
Rex1 Fw GCTCCTGCACACAGAAGAAA RT-qPCR 5 
Rex1 Rv GTCTTAGCTGCTTCCTTCTTGA RT-qPCR 5 
Stella Fw AAAGTCGACCCAATGAAGGA RT-qPCR 4 
Stella Rv ACACCGGGGTTTAGGGTTAG RT-qPCR 4 
Gapdh Fw TGGAGAAACCTGCCAAGTATGA RT-qPCR 1 
Gapdh Rv GTTGCTGTTGAAGTCGCAGG RT-qPCR 1 
Dlk1 S1 F GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG 
GTGTTTATTAGTTTGGTGGTG 
Bsulfite PCR this work 
Dlk1 S1 R CGACGCTCTTCCGATCTACTTAAATCTCCTCATCACCA Bsulfite PCR this work 
H19 S2 F GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAAGAGAGAAGAA
GGAGATTTATTTGT 
Bsulfite PCR this work 
H19 S2 R CGACGCTCTTCCGATCTCATCTAAAATCTAACAAAAATATTAAAAA Bsulfite PCR this work 
H19 S3 F GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATTATAATGGGA
ATTTGAGGGTA 
Bsulfite PCR this work 
H19 S3 R CGACGCTCTTCCGATCTTAACCAAAACCAAACTATAAAATAACTAAT Bsulfite PCR this work 
Nesp S1a F GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGAGTTTTTTGAA
TTTGAGTTTGAT 
Bsulfite PCR this work 
Nesp S1a R CGACGCTCTTCCGATCTTAAATAACTAATTAAAAATAACACCC Bsulfite PCR this work 
Nesp S2 F GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGAGGTTAAAGG
TTTGTTGG 
Bsulfite PCR this work 





Bsulfite PCR this work 
Magel2-Mrkn3 
S1b R 
CGACGCTCTTCCGATCTATTCTCCAACTTCTACTCTCA Bsulfite PCR this work 
Cdkn1c 2 F GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTTGTGAAATTG
AAAATATTATATTATGTT 
Bsulfite PCR this work 
Cdkn1c 2 R CGACGCTCTTCCGATCTTAAATAAAACCCCTTACACAACC Bsulfite PCR this work 
Nextera i7 CAAGCAGAAGACGGCATACGAGATNNNNNNNNGTCTCGTGGGCTC
GG 
Indexing this work 
TruSeq i5 AATGATACGGCGACCACCGAGATCTACACNNNNNNNNACACTCTTT
CCCTACACGACGCTCTTCCGATCT 
Indexing this work 
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Supplementary Table 2 (related to Extended Data Figure 2b) 
Size, numbers of CpG sites and genomic coordinates of regions targeted within secondary 
imprints (sDMRs). 
 
sDMR genomic coordinates (mm10) Size (bp) CpGs 
    
Dlk1 chr12:109,460,142-109,460,363 221 9 
H19 S2 chr7:142,577,743-142,578,043 300 9 
H19 S3 chr7:142,578,512-142,578,757 245 7 
Nesp S1a chr2:174,284,913-174,285,161 248 23 
Nesp S2 chr2:174,285,645-174,285,827 182 10 
Magel2-Mrkn3 chr7:62,406,768-62,407,043 275 15 
Cdkn1c chr7:143,460,795-143,461,100 305 28 
 
  





Unless noted otherwise, all reactions were performed using oven dried glassware under an 
atmosphere of argon. Molsieve-dried solvents were used from Sigma Aldrich and chemicals 
were bought from Sigma Aldrich, TCI, Carbolution and Carbosynth. For extraction and 
chromatography purposes, technical grade solvents were distilled prior to their usage. 
Reaction controls were performed using TLC-Plates from Merck (Merck 60 F254), flash column 
chromatography purifications were performed on Merck Geduran Si 60 (40-63 M). 
Visualization of the TLC plates was achieved through UV-absorption. NMR spectra were 
recorded in deuterated solvents on Varian VXR400S, Varian Inova 400, Bruker AMX 600, 
Bruker Ascend 400 and Bruker Avance III HD. HR-ESI-MS spectra were obtained from a 
Thermo Finnigan LTQ FT-ICR. IR-measurements were performed on a Perkin Elmer Spectrum 
BX. HPLC purifications were performed on a Waters Breeze system (2487 dual array detector, 
1525 binary HPLC pump) using a Nucleosil VP 250/10 C18 column from Macherey Nagel. 
HPLC-grade MeCN was purchased from VWR.  
 








Na2CO3 (6.57 g, 62.0 mmol, 1.5 Equiv.) was dissolved in D2O (25 mL), propionic acid (2.60 mL, 
42.0 mmol, 1.0 Equiv.) was added dropwise over 3 min. The reaction was stirred for 18 h at rt, 
the solvent was removed under reduced pressure, another portion of D2O (21 mL) was added 
and the mixture was stirred for 14 h at rt. Through addition of D2SO4 the pH value of the mixture 
was adjusted to 1. The mixture was extracted with DCM, the organic layers were dried over 
MgSO4, all the volatiles were removed under reduced pressure (600 mbar, 40 °C). Purification 
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by fractional distillation (27 mbar,39 °C) yielded [D2]-propionic acid (452 mg, 6.27 mmol, 15 %) 




[15N2]-Urea (150 mg, 2.41 mmol, 1.0 Equiv.) was dissolved in D2SO4 (3 mL) and [D2]-propiolic 
acid (0.161 mL, 2.65 mmol, 1.1 Equiv.) was added dropwise. The mixture was stirred at 105 °C 
for 18 h. The brown suspension was diluted with water (50 mL) and the pH value was adjusted 
to 10 with Na2CO3. Volatiles were removed under reduced pressure and the crude was purified 
by flash column chromatography (DCM/MeOH 4:1). A mixture of [D2, 15N2]-uracil (101 mg, 
0.864 mmol, 36 %) und [D, 15N2]-uracil (50 mg, 0.43 mmol, 18 %) was obtained as a colorless 
solid. 
1H-NMR (400 MHz, DMSO-d6) δ 11.03 (dd, 1J = 77.2 Hz, 4J = 1.8 Hz, 1H, N3-H), 10.80 (dd,1J 
= 82.6 Hz, 4J = 1.9 Hz, 1H, N1-H), 5,46 (dd, 3J = 4.3 Hz, 4J = 2.5 Hz, C5-H) ppm. 
13C-NMR (101 MHz, DMSO-d6) δ 164.9 (t, 1J = 9.7 Hz, C4), 151.9 (m, C2), 142.3 (m, C6), 






The mixture of [D2, 15N2]-uracil und [D, 15N2]-uracil (37 mg, 0.32 mmol, 1.0 Equiv.) was 
dissolved in MeCN (2 mL). Bis-(trimethylsilyl)acetamide (0.3 mL, 0.96 mmol, 3.0 Equiv.) was 
added dropwise and the reaction mixture was stirred for 3 h at 80 °C. All volatiles were removed 
under reduced pressure and the residue was coevaporated with chloroform (3 x 6 mL). The 
residue was dissolved in chloroform(2 mL) and Hoffer’s chlorosugar (149 mg,0.383 mmol, 
1.2 Equiv.) was added and stirred at rt for 17 h. After removing of the volatiles under reduced 
Spada et al.  Supplementary Information 
9 
 
pressure, purification by flash column chromatography (iHex/EtOAc 1:1) yielded a mixture of 
α-[D2, 15N2]-3’,5’-bis-O-(p-toluoyl)-2’-deoxyuridine β-[D, 15N2]-3’,5’-bis-O-(p-toluoyl)-2’-
deoxyuridine (41 mg, 0.088 mmol, 28 %, α/β: 1.28:1) as a yellow foam. 
α-[D2, 15N2]-3’,5’-Bis-O-(p-toluoyl)-2’-deoxyuridine: 
1H-NMR (400 MHz, CDCl3): δ = 9.06 (d, 1J = 91.0 Hz, 1H, NH), 7.89 (d, 3J = 8.0 Hz, 2H, Tol2), 
7.78 (d, 3J = 8.0 Hz, 2H, Tol2), 7.31-7.20 (m, 4H, Tol3), 6.31 (d, 3J = 6.8 Hz, 1H, C1’- H), 5.72 
(dt, 3J = 4.7 Hz, 3J = 2.4 Hz, 1H, C5-H), 5.61 (m, 1H, C3’-H), 4.86 (t, 3J = 4.3 Hz, 1H, C4’-H), 
4.54 (m, 2H, C5’-H), 3.01-2.89 (m, 1H, C2’-H), 2.55 (d, 3J = 15.5 Hz, 1H, C2’-H), 2.43 (s, 3H, 
CH3), 2.41 (s, 3H, CH3) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 165.7 (COO), 166.1 (COO), 150.1 (C2), 144.9 (Tol4), 144.4 
(Tol4), 129.7 (Tol2), 129.6 (Tol2), 129.5 (Tol3), 129.4 (Tol3), 126.5 (Tol1), 125.9 (Tol1), 101.4 
(C5), 88.0 (d, 1J = 10.0 Hz, C1’), 85.7 (C4’), 74.7 (C3’), 64.0 (C5’), 39.0 (C2’), 21.7 (CH3) ppm. 
β-[D2, 15N2]-3’,5’-Bis-O-(p-toluoyl)-2’-deoxyuridine: 
1H-NMR (400 MHz, CDCl3): δ = 8.93 (d, 1J = 91.0 Hz, 1H, NH), 7.94 (d, 3J = 8.0 Hz, 2H, Tol2), 
7.93 (d, 3J = 8.0 Hz, 2H, Tol2) 7.31-7.20 (m, 4H, Tol3), 6.41 (dd, 3J = 8.3 Hz, 3J = 5.7 Hz, 1H, 
C1’-H), 5.60 (m, 2H, C3’-H und C5-H), 4.73 (dd, 3J = 12.3 Hz, 4J = 3.1 Hz, 1H, C5’-H), 4.67 
(dd, 3J = 12.3 Hz, 4J = 3.5 Hz, 1H, C5’-H), 4.60-4.49 (m, 1H, C4’-H), 2.75 (dd, 3J = 14.3 Hz, 3J 
= 5.7 Hz, 1H, C2’-H), 2.43 (s, 6H, CH3), 2.30 (m, 1H, C2’-H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 165.7 (COO), 166.1 (COO), 150.1 (C2), 144.7 (Tol4), 129.9 
(Tol2), 129.5 (Tol2), 129.4 (Tol3), 129.3 (Tol3), 126.5 (Tol1), 125.9 (Tol1), 101.4 (C5), 85.4 (d, 
1J = 12.8 Hz, C1’) 83.0 (C4’), 74.7 (C3’), 64.0 (C5’), 38.4 (C2’), 21.7 (CH3) ppm. 






A mixture of α-[D2, 15N2]-3’,5’-bis-O-(p-toluoyl)-2’-deoxyuridine and β-[D2, 15N2]-3’,5’-bis-O-(p-
toluoyl)-2’-deoxyuridine (267 mg, 0.570 mmol, 1.0 Equiv.) was dissolved in MeCN (6 mL), LiI 
(92 mg, 0.68 mmol, 1.2 Equiv.) and ceric(IV)-ammoniumnitrate (625 mg, 1.14 mmol, 
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2.0 Equiv.) were added. The suspension was stirred at 80 °C for 3 h. After full conversion of 
the starting material, saturated aq. NaCl-solution (30 mL) was added, mixture was extracted 
with DCM, the combined organic layers were dried oved MgSO4 and all volatiles were removed 
under reduced pressure. Purification by flash column chromatography (iHex/EtOAc 1:1) 
yielded β-[D, 15N2]-3’,5’-bis-O-(p-toluoyl)-5-iodo-2’-deoxyuridine 33 (177 mg,0.298 mmol, 
52 %) as a yellow solid. 
1H-NMR (400 MHz, CDCl3): δ = 8.99 (d, 1J = 93.6 Hz, 1H, NH), 7.94 (d, 3J = 3.5 Hz, 2H, Tol2), 
7.92 (d, 3J = 3.6 Hz, 2H, Tol2), 7.27 (d, 3J = 7.7 Hz, 4H, Tol3), 6.37 (dd, 3J = 8.7 Hz, 3J = 5.4 
Hz, 1H, C1’-H), 5.61 (d, 3J = 6.6 Hz, 1H, C3’-H), 4.73 (t, 3J = 2.7 Hz, 2H, C5’-H), 4.57 (q, 3J = 
2.7 Hz, 1H, C4’-H), 2.78 (dd, 3J = 14.3, 3J = 5.5 Hz, 1H, C2’-H), 2.43 (s, 3H, CH3), 2.42 (s, 3H, 
CH3), 2.28 (m, 1H, C2’-H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 166.1 (COO), 166.0 (COO), 159.6 (d, 1J = 10.4 Hz, C4), 149.7 
(t, 1J = 18.9 Hz, C2), 144.7 (Tol4), 144.6 (Tol4), 129.9 (Tol2), 129.7 (Tol2), 129.6 (Tol3), 129.3 
(Tol3), 126.4 (Tol1), 126.2 (Tol1), 85.8 (d, 1J = 12.3 Hz, C1’), 83.5 (C4’), 74.9 (C3’), 68.8 (d, 2J 
= 9.0 Hz, C5), 64.2 (C5’), 38.8 (C2’), 21.8 (CH3) ppm. 






1,2,4-Triazole (42 mg, 0.60 mmol, 9.0 Equiv.) was dissolved in MeCN (1 mL), POCl3 
(0.028 mL, 0.29 mmol, 4.4 Equiv.) was added dropwise at 0 °C, the mixture was stirred for 
10 min at 0 °C, NEt3 (0.084 mL,0.60 mmol, 9.0 Equiv.) was added and the reaction solution 
was stirred at rt for 20 min. A solution of β-[D, 15N2,]-3’,5’-bis-O-(p-Toluoyl)-5-iodo-2’-
deoxyuridine (40 mg, 0.07 mmol, 1.0 Equiv.) in MeCN (1.5 mL) was added to the reaction and 
stirred at 30 °C for 18 h. After full conversion of the starting material, NEt3 (0.4 mL) und H2O 
(0.1 mL) were added and stirred for 10 min at 30 °C. Saturated aq. NaCl-solution (5 mL) and 
saturated aq. NaHCO3-solution (5 mL) were cooled down to 0 °C and added to the reaction 
mixture. The solution was extracted with DCM, the combined organic layers were dried over 
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MgSO4 and all volatiles were removed under reduced pressure. The residue was dissolved in 
1,4-dioxane (10 mL) and a concentrated NH3-solution (1.5 mL) was added. The reaction 
mixture was stirred for 15 min at 30 °C, afterwards an aqueous NH4Cl-solution (10 mL) was 
added and extracted with DCM. The combined organic layers were dried over MgSO4 and the 
volatiles were removed under reduced pressure. Purification of the crude by flash column 
chromatography (DCM/MeOH 50:1) yielded [D, 15N2]-3’,5’-bis-O-(p-toluoyl)-5-iodo-2’-
deoxycytidine (17 mg, 0.029 mmol, 43 %) as a yellow solid. 
1H-NMR (400 MHz, CDCl3): δ = 7.94 (d, 3J = 8.0 Hz, 2H, Tol2), 7.90 (d, 3J = 8.1 Hz, 2H, Tol2), 
7.29-7.22 (m, 4H, Tol3), 6.36 (dd, 3J = 8.4 Hz, 3J = 5.4 Hz, 1H, C1’-H), 5.58 (d, 3J = 6.4 Hz, 
1H, C3’-H), 5.49 (s, 2H, NH2), 4.76 (dd, 3J = 12.3 Hz, 3J = 3.0 Hz, 1H, C5’-H), 4.68 (dd, 3J = 
12.3 Hz, 3J = 3.4 Hz, 1H, C5’-H), 4.59 (q, 3J = 2.7 Hz, 1H, C4’-H), 3.02-2.92 (m, 1H, C2’-H), 
2.42 (s, 3H, CH3), 2.41 (s, 3H, CH3), 2.17 (m, 1H, C2’-H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 166.1 (COO), 163.7 (C4), 154.9 (C2), 144.5 (Tol4) 144.5 
(Tol4), 129.8 (Tol2), 129.7 (Tol2), 129.5 (Tol3), 129.3 (Tol3), 126.4 (Tol1), 126.3 (Tol1), 87.1 
(d, 1J = 11.2 Hz, C1’), 83.6 (C4’), 75.3 (C3’), 64.2 (C5’), 56.1 (C5), 39.5 (C2’), 21.8 (CH3) ppm. 
HRMS (ESI+): m/z calculated [C25H24DO6N15N2I]+ ([M+H]+): 593.0792, found: 593.0791. 
 
5-[D3]-Methyl-2’-deoxy-[6-D, 1,3-15N2]-cytidine  
 
Ni(dppp)Cl2 (8 mg, 0.01 mmol, 0.5 Equiv.) was dried in a schlenk flask under high vacuum for 
30 min. A solution of β-[D, 15N2]-3’,5’-bis-O-(p-toluoyl)-5-iodo-2’-deoxycytidine (17 mg, 
0.029 mmol, 1.0 Equiv.) in THF (1 mL) was added at 0 °C. Afterwards D3CMgI (0.072 mL, 
0.072 mmol, 2.5 Equiv.) was added dropwise and the mixture was stirred at rt for 1.5 h. Another 
portion of D3CMgI (0.072 mL, 0.072 mmol, 2.5 Equiv.) was added dropwise and stirred for 1 h 
at rt. A third portion of D3CMgI (0.20 mL, 0.20 mmol, 6.9 Equiv.) and Ni(dppp)Cl2 (8 mg, 
0.01 mmol, 0.5 Equiv.) were added to the mixture and stirred for17 h at rt. A saturated aqueous 
NH4Cl-solution (8 mL) was added to the reaction solution and extracted with EtOAc. The 
combined organic layers were dried MgSO4 and all volatiles were removed under reduced 
pressure The residue was purified by flash column chromatography (DCM/MeOH 20:1) to yield 
a mixture of β-5-[D3]-methyl-3’,5’-bis-O-(p-toluoyl)-2’-deoxy-[D,15N2,]-cytidine and β-3’,5’-bis-
O-(p-toluoyl)-2’-deoxy-[D, 15N2,]-cytidine as a yellow foam. 
The resulting mixture was dissolved in MeOH (1.2 mL), K2CO3 (13 mg, 0.094 mmol, 4.7 Equiv.) 
was added and the solution was stirred for 18 h at rt. Another portion of K2CO3 (13 mg, 
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0.094 mmol, 4.7 Equiv.) and MeOH (1.2 mL) was added and stirred for 17 h at rt. The volatiles 
were removed under reduced pressure and the residue was purified via HPLC (Macherey-
Nagel, Nucleosil 100-7 C18, 10 × 250 mm, linear gradient, 0 % - 10 % MeCN in water in 
45 min) to yield [D4, 15N2]-m5dC (0,9 mg,0,004 mmol, 12 %) as a colorless solid.  
1H-NMR (800 MHz, D2O): δ = 6.30 (t, 3J = 6.7 Hz, 1H, C1’-H), 4.46 (dt, 3J = 6.6 Hz, 3J = 4.1 
Hz, 1H, C3’-H), 4.05 (q, 3J = 4.2 Hz, 1H, C4’-H), 3.86 (dd, 3J = 12.5 Hz, 3J = 3.6 Hz, 1H, C5’-
H), 3.78 (dd, 3J = 12.5 Hz, 3J = 5.1 Hz, 1H, C5’-H), 2.47-2.36 (m, 1H, C2’-H), 2.38-2.25 (m, 1H, 
C2’-H) ppm. 
13C-NMR (201 MHz, D2O): δ = 89.1 (C4’), 88.4 (d, 1J = 13.0 Hz, C1’), 73.1 (C3’), 63.8 (C5’), 
41.8 (C2’) ppm. 
HRMS (ESI+): m/z calculated [C10H12D4O4N15N2]+ ([M+H]+): 248.1327, found: 248.1326. 
 




5-formyl-2'-deoxy-(1',2',3',4',5'-13C5, N1,N3-15N2)-cytidine was prepared according to Iwan et 
al.6 
 




5-formyl-2'-deoxy-(1',2',3',4',5'-13C5, N1,N3-15N2)-cytidine (7.4 mg, 0.028 mmol, 1.0 Equiv.), 
CeCl3*7H2O (32 mg, 0.085 mmol, 3.0 Equiv.) and NaBH4 (1.0 mg, 0.028 mmol, 1.0 Equiv.) 
were dissolved in MeOH and stirred for 5 min at rt. Saturated aqeous NH4Cl solution was 
added and the mixture was concentrated under reduced pressure. Purification via HPLC 
(Macherey-Nagel, Nucleosil 100-7 C18, 10 × 250 mm, linear gradient, 0 % - 10 % MeCN in 
Spada et al.  Supplementary Information 
13 
 
water in 60 min) yielded 5-hydoxymethyl-2'-deoxy-(1',2',3',4',5'-13C5, N1,N3-15N2)-cytidine 
(quant.). 
HRMS (ESI+): m/z calculated [C513C5H16O5N15N2]+ ([M+H]+): 265.1193, found: 265.1190. 
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